Apellis Pharmaceuticals News and Activities

Apellis Pharmaceuticals is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Apellis Pharmaceuticals is a company listed under the stock ticker APLS (US).

View the org chart displaying its 21 main executives

Most searched biographies at Apellis Pharmaceuticals

• Cedric Francois, Chief Executive Officer and Director
• Stephanie Monaghan O'Brien, Director
• Gerald Chan, Chairman of the Board

Popular executive movements at Apellis Pharmaceuticals

• Jason Raines, Senior Vice President, Development Operations, has left the company  (posted on April 21 2025).
• Karen Lewis, Chief People Officer, has left the company  (posted on April 21 2025).
• Craig Wheeler has joined the company as Directors  (posted on April 21 2025).

Click here to view some more movements at Apellis Pharmaceuticals

Create your alert
to follow the executive moves at Apellis Pharmaceuticals.

Apellis Pharmaceuticals has 2,349 competitors including Astellas Gene Therapies (United States (USA)), Eurofins (Luxembourg) and BitBiome (United States (USA)).

Popular M&A news in Biotechnology

• Actio Biosciences has just announced a $66 Million fundraising (posted on June 19 2025).
• Prenetics has just announced a $20 Million fundraising (posted on June 19 2025).
• Draig Therapeutics has just announced a $140 Million fundraising (posted on June 18 2025).

Popular contacts in Biotechnology

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships at WIRB-Copernicus Group
• Jasbir Seehra - Chief Executive Officer and Chairman of the Board at Keros Therapeutics
• Andrea Jackson - Director at Ultivue

Learn more about the Biotechnology industry

Press releases by Apellis Pharmaceuticals

• Apellis Announces 18-Month Data from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy (GA) | Apellis Pharmaceuticals, Inc.
• Apellis Announces New Data Demonstrating Correlation between Complement Activation and COVID-19 Severity | Apellis Pharmaceuticals, Inc.
• Apellis to Present Positive Results from the Phase 2 DISCOVERY Study of Pegcetacoplan in C3 Glomerulopathy (C3G) at ASN Kidney Week | Apellis Pharmaceuticals, Inc.
• Apellis Initiates Registrational Programs of Pegcetacoplan in Patients with C3G / IC-MPGN and ALS, Rare Diseases with High Unmet Need | Apellis Pharmaceuticals, Inc.
• Apellis Announces New Analysis Demonstrating Targeted C3 Therapy Pegcetacoplan Slows Progression of Early Disease in Patients with Geographic Atrophy (GA) | Apellis Pharmaceuticals, Inc.
• Apellis Pharmaceuticals to Present at Stifel’s 2020 Immunology and Inflammation Virtual Summit | Apellis Pharmaceuticals, Inc.
• Apellis Announces Late-Breaking Presentation of Targeted C3 Therapy Pegcetacoplan in Patients with Geographic Atrophy (GA) at EURETINA 2020 | Apellis Pharmaceuticals, Inc.
• Apellis Announces Submission of Pegcetacoplan Marketing Applications to FDA and EMA for Patients with PNH | Apellis Pharmaceuticals, Inc.
• Apellis Pharmaceuticals to Present at Upcoming Investor Conferences | Apellis Pharmaceuticals, Inc.
• Apellis Pharmaceuticals Reports Second Quarter 2020 Financial Results | Apellis Pharmaceuticals, Inc.
• View more press releases Close

Social media about Apellis Pharmaceuticals

• Apellis Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Apellis Pharmaceuticals on LinkedIn, Twitter & YouTube